News

FDA Accepts IND for Poseida Therapeutics’ Allogeneic CAR-T Cell Therapy Candidate

January 07, 2022

FDA has cleared an IND from Poseida Therapeutics, allowing continued development of the company’s allogeneic CAR-T cell therapy candidate for treating multiple solid tumors.

Insightful Science Completes Acquisition of Protein Metrics

January 07, 2022

The acquisition of Protein Metrics expands Insightful Science’s R&D solutions to include proteomics.

BAT Launches Biotech Company to Accelerate the Development of Novel Medicines

January 07, 2022

BAT has launched KBio Holdings—a biotech focused on the acceleration of research, development, and production of novel medicines that leverage plant-based technology.

BBI Solutions Acquires BioTeZ Berlin-Buch

January 07, 2022

BBI Solutions has completed the acquisition of BioTeZ Berlin-Buch—a Germany-based manufacturer of reagents and finished tests for the in-vitro diagnostics market.

Clinical Trial on Intranasal Coronavirus Vaccine Set to Start

January 07, 2022

Intravacc is partnering with Leiden University Medical Center for the development and evaluation of a new intranasal coronavirus vaccine candidate in a clinical Phase I/II study.

Pharming Gains Nod from EMA on PIP for Leniolisib

January 07, 2022

Pharming Group, has been granted a positive opinion by EMA for its Paediatric Investigation Plan for leniolisib.

Piramal Pharma Invests Minority Stake in India-Based CDMO, Yapan Bio

January 05, 2022

With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.

FDA Keeps New Drugs Coming

January 05, 2022

FDA maintained a steady pace in 2021 in approving important new therapies for market, including new vaccines and treatments for COVID-19.

New High Fidelity CRISPR Cas9 Protein Reduces Off-Target Effects

January 04, 2022

Thermo Fisher Scientific’s Invitrogen TrueCut HiFi Cas9 Protein offers the advantage of significantly minimizing off-target events while aiming to retain maximum on-target editing efficiency.

OpenEye Scientific and Specifica Partner to Launch Orion Antibody Discovery Suite

January 04, 2022

The partnership between OpenEye Scientific and Specifica has generated AbXtract, an antibody discovery model that is included in the Orion Antibody Suite.